• Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL; Note=BCR exon 13 fused to ABL1 exon 2 (b2a2 transcript) (from parent cell line).
  
• Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Leufs*5 (c.3261dupC) (3261_3262insC); ClinVar=VCV000089364; Zygosity=Heterozygous (from parent cell line).
  
• Mutation; HGNC; 11998; TP53; Simple; p.Pro301Glnfs*44 (c.902delC); ClinVar=VCV000233908; Zygosity=Homozygous (from parent cell line).
  

PubMed=10910924; DOI=10.1182/blood.V96.3.1070
Mahon F.-X., Deininger M.W.N., Schultheis B., Chabrol J., Reiffers J., Goldman J.M., Vaz de Melo J.
Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance.
Blood 96:1070-1079(2000)

PubMed=17549412; DOI=10.3892/ijo.31.1.121
Hentschel J., Weise A., Michel S., Hennig K., Hartmann I., Schiefner J., Schubert K., Liehr T., von Eggeling F., Loncarevic I.F.
Cytogenetic characterisation and proteomic profiling of the Imatinib-resistant cell line KCL22-R.
Int. J. Oncol. 31:121-128(2007)

PubMed=20417730; DOI=10.1016/j.bbapap.2010.04.009
Colavita I., Esposito N., Martinelli R., Catanzano F., Vaz de Melo J., Pane F., Ruoppolo M., Salvatore F.
Gaining insights into the Bcr-Abl activity-independent mechanisms of resistance to imatinib mesylate in KCL22 cells: a comparative proteomic approach.
Biochim. Biophys. Acta 1804:1974-1987(2010)

PubMed=23754495; DOI=10.1002/pmic.201200444
Colavita I., Esposito N., Quintarelli C., Nigro E., Pane F., Ruoppolo M., Salvatore F.
Identification of annexin A1 interacting proteins in chronic myeloid leukemia KCL22 cells.
Proteomics 13:2414-2418(2013)